• Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024

• The Waltham Massachusetts-based company is expected to report a 66.7% decrease in revenue to $10.33 thousand from $31 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Checkpoint Therapeutics Inc is for a loss of 15 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Checkpoint Therapeutics Inc is $20.00​, above​ its last closing price of $3.46. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated November 8 at 21:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)